Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Summary of Significant Accounting Policies (Tables)

v3.24.1.1.u2
Nature of Business and Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share

The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 

 

 

Three Months Ended
March 31,

 

 

 

2024

 

 

2023

 

Shares issuable upon exercise of stock options

 

 

8,060,978

 

 

 

7,217,915

 

Shares issuable upon exercise of warrants

 

 

6,272,508

 

 

 

796,985